Success Metrics

Clinical Success Rate
87.3%

Based on 247 completed trials

Completion Rate
87%(247/283)
Active Trials
18(5%)
Results Posted
51%(127 trials)
Terminated
36(10%)

Phase Distribution

Ph phase_2
142
39%
Ph phase_4
68
18%
Ph phase_3
43
12%
Ph phase_1
77
21%
Ph not_applicable
21
6%
Ph early_phase_1
15
4%

Phase Distribution

92

Early Stage

142

Mid Stage

111

Late Stage

Phase Distribution366 total trials
Early Phase 1First-in-human
15(4.1%)
Phase 1Safety & dosage
77(21.0%)
Phase 2Efficacy & side effects
142(38.8%)
Phase 3Large-scale testing
43(11.7%)
Phase 4Post-market surveillance
68(18.6%)
N/ANon-phased studies
21(5.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.3%

247 of 300 finished

Non-Completion Rate

17.7%

53 ended early

Currently Active

18

trials recruiting

Total Trials

368

all time

Status Distribution
Active(23)
Completed(247)
Terminated(53)
Other(45)

Detailed Status

Completed247
unknown44
Terminated36
Withdrawn17
Recruiting11
Active, not recruiting7

Development Timeline

Analytics

Development Status

Total Trials
368
Active
18
Success Rate
87.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 115 (4.1%)
Phase 177 (21.0%)
Phase 2142 (38.8%)
Phase 343 (11.7%)
Phase 468 (18.6%)
N/A21 (5.7%)

Trials by Status

recruiting113%
withdrawn175%
active_not_recruiting72%
suspended10%
terminated3610%
completed24767%
not_yet_recruiting31%
unknown4412%
enrolling_by_invitation21%

Recent Activity

Clinical Trials (368)

Showing 20 of 368 trialsScroll for more
NCT02954978Phase 2

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

Completed
NCT05870111Phase 2

Citicoline in Youth Alcohol Use Disorder

Active Not Recruiting
NCT04002674Phase 2

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Completed
NCT03675724Phase 2

Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults

Enrolling By Invitation
NCT07584369Phase 4

Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study

Not Yet Recruiting
NCT03430037Phase 2

Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women

Enrolling By Invitation
NCT04181996Phase 3

Canadian Study of Arterial Inflammation in Patients With Diabetes and Vascular Events: EvaluatioN of Colchicine

Completed
NCT03030248Phase 2

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

Completed
NCT03825536Phase 4

Effect of Methamphetamine on Residual Latent HIV Disease Study

Completed
NCT03850964Phase 2

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

Active Not Recruiting
NCT05350215Phase 1

Atomoxetine and DAW2022 on OSA Severity

Recruiting
NCT05288855Phase 3

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

Terminated
NCT05207085Phase 2

Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults

Recruiting
NCT03325322Phase 2

Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease

Suspended
NCT07022353Not Applicable

Bi-level Erector Spinae Plane Block and Pre-emptive Oral Tizanidine for Analgesia After Mastectomy Surgery

Completed
NCT03667326Phase 2

Postpartum Low-Dose Aspirin and Preeclampsia

Recruiting
NCT05589792Phase 1

Acetazolamide on REM OSA

Completed
NCT06790537Phase 4

Efficacy of Pregabalin for Diabetic Pruritus - A Randomized Controlled Study.

Recruiting
NCT03420482Phase 2

Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy

Active Not Recruiting
NCT06617312Phase 2

Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
368